Science for Life Laboratory Joins the Illumina Genome Network

First European Genome Network Partner Plans Large Scale Population Sequencing Program

SAN DIEGO--(BUSINESS WIRE)--Feb. 24, 2014-- Illumina, Inc. (NASDAQ:ILMN) today announced that Science for Life Laboratory (SciLifeLab) in Sweden has joined the Illumina Genome Network (IGN) to provide researchers with broader access to Illumina’s whole genome sequencing technology. SciLifeLab is the first IGN partner in Europe and will initiate a national large-scale population sequencing program seeking to identify genetic causes of human diseases.

“We now have the opportunity to offer an even larger capacity of high throughput sequencing to researchers from all over Sweden. In the research program we are about to launch, we aim to sequence more than 1,000 human genomes using the Illumina systems,” said Joakim Lundeberg, Professor in Gene Technology at KTH Royal Institute of Technology and Director of the National Genomics Infrastructure at Science for Life Laboratory.

“We are very excited to welcome the SciLifeLab to our prestigious group of IGN partners and to work with them on their groundbreaking national genome sequencing project,” said Alex Dickinson, Senior Vice President Strategic Initiatives for Illumina. “We look forward to working with SciLifeLab to speed genetic discovery and establish a map of genetic variability in Sweden.”

IGN links researchers needing large-scale, whole human genome sequencing with world class institutions that provide this service, and delivers unmatched access to the highest quality of whole genome sequencing data. All IGN partners are experienced and well-published using Illumina’s next-generation sequencing technology, and have completed Illumina’s Certified Service Provider (CSPro) certification. Each possesses ten or more Illumina high-throughput sequencing systems, providing the scalability to handle large sequencing projects with rapid completion times.

SciLifeLab joins twelve other IGN partners who provide a full range of WGS services:

• British Columbia Cancer Agency in Vancouver, Canada
• The Broad Institute in Cambridge, Massachusetts
• Cold Spring Harbor Laboratory in Cold Spring Harbor, New York
• HudsonAlpha Institute for Biotechnology in Huntsville, Alabama
• Macrogen & Genomic Medicine Institute in Seoul, Korea
• McGill University in Montreal, Canada
• National Center for Genome Resources in Santa Fe, New Mexico
• New York Genome Center in New York, New York
• Northwest Genomics Center at University of Washington in Seattle, Washington
• Peking University in Beijing, China
• Takara Bio, Shiga, Japan
• Illumina’s FastTrack Services lab in San Diego, California

For more information about the Illumina Genome Network, please visit http://www.illumina.com/IGN.

About Illumina

Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.

About SciLifeLab

Science for Life Laboratory (SciLifeLab) is a Swedish national center for molecular biosciences with focus on health and environmental research. The center combines frontline technical expertise with advanced knowledge of translational medicine and molecular bioscience. SciLifeLab is a joint effort between four Swedish universities (Karolinska Institutet, KTH Royal Institute of Technology, Stockholm University and Uppsala University).

SciLifeLab was established in 2010 and appointed a national center in 2013 by the Swedish government. More than 200 research groups are associated with SciLifeLab, which is situated at two nodes in Stockholm and Uppsala.

Forward-Looking Statements

This release may contain forward looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.

Source: Illumina, Inc.

Illumina, Inc.
Investors:
Rebecca Chambers
858-255-5243
rchambers@illumina.com
or
Media:
Jennifer Temple
858-882-6822
pr@illumina.com